Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.43 |
| ▸ | PPARA | Q07869 | 18/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017767 | 0.84 | PPARA (0.61) | PPARGPPARA | |
| SCHEMBL4012672 | 0.66 | PPARA (0.65) | PPARGPPARA | |
| SCHEMBL7313279 | 0.61 | MAOA (0.43) | ALDH1A1POLBMAPT | |
| SCHEMBL4019100 | 0.61 | PPARA (1.00) | PPARGPPARA | |
| SCHEMBL4013093 | 0.60 | PPARA (0.80) | PPARGPPARA | |
| SCHEMBL4014883 | 0.60 | PPARA (0.69) | PPARGPPARA | |
| SCHEMBL11789966 | 0.59 | PPARG (0.54) | PPARGPPARAALDH1A1HPGD | |
| Butane SCHEMBL10985150 | 0.58 | USP5 (0.59) | PPARGPPARAMEN1ALDH1A1POLB | |
| SCHEMBL3404341 | 0.57 | USP5 (0.63) | PPARGPPARAMEN1ALDH1A1POLB | |
| SCHEMBL7445813 | 0.57 | ADRA2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2006-06-08 | — | — | US | disclosed |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885MEN1 4882/4885 |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885MEN1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.